UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations

/in , , , /by

New phase 1/2 results published in the Journal of Clinical Oncology provide further evidence of the clinical activity of bavdegalutamide (ARV-110), an experimental androgen receptor (AR) degrader, in patients with metastatic castration-resistant prostate cancer (mCRPC). The findings suggest that specific AR mutations may help identify patients most likely to benefit from this treatment. Unlike conventional […]

Read more

UPDATE: TheraPb Reports 11.2-Month Median rPFS With 212Pb-ADVC001

/in , , , /by

Updated results from the TheraPb phase 1 trial, presented at ESMO 2026, provide longer-term follow-up for ²¹²Pb-ADVC001, an experimental PSMA-targeted alpha radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC). The study enrolled 22 heavily pretreated patients across different dose levels and treatment schedules. With an additional 12 months of observation and a median follow-up of […]

Read more

PEACE-1: Triplet Therapy Shows Lasting Survival Benefit at Eight Years

/in , , /by

After a median follow-up of 7.7 years, the phase 3 PEACE-1 trial confirms a lasting survival benefit from adding abiraterone and prednisone to standard treatment for men diagnosed with metastatic hormone-sensitive prostate cancer. The trial enrolled 1,173 men and tested the addition of abiraterone, prostate radiotherapy, or both to androgen deprivation therapy (ADT), with or […]

Read more

UPDATE: JNJ-6143 Shows Early Activity in Advanced Prostate Cancer

/in , , /by

Updated phase 1 results provide further evidence of activity for JNJ-6143, previously known as HLD-0915 and also referred to as JNJ-101556143, in heavily pretreated metastatic castration-resistant prostate cancer. Following our previous coverage of its initial results and a separate phase 2 trial, the new findings add dose-specific outcomes and exploratory molecular data. JNJ-6143 is an […]

Read more

Phase 1 ProTACT: Actinium-225 FL-020 Shows Early Activity in Advanced Prostate Cancer

/in , , /by

New results show preliminary antitumor activity for 225Ac-FL-020, an investigational PSMA-targeted alpha radioligand, in patients with metastatic castration-resistant prostate cancer (mCRPC). The findings come from ProTACT, an ongoing first-in-human phase 1 trial evaluating the safety, dosing, and preliminary efficacy of FL-020 in patients previously treated with androgen receptor pathway inhibitors and taxane chemotherapy, unless chemotherapy […]

Read more

UPDATE: EIK1003 Plus Abiraterone Shows Early Activity in HRR-Mutated Prostate Cancer

/in , , , /by

New results provide updated safety and efficacy data for EIK1003 (formerly IMP1734), an investigational selective PARP1 inhibitor, in combination with abiraterone and prednisone in patients with metastatic prostate cancer harboring homologous recombination repair (HRR) gene alterations. Unlike conventional PARP inhibitors, EIK1003 selectively targets PARP1 while largely sparing PARP2, potentially reducing the hematological toxicity associated with […]

Read more

UPDATE: CONVERGE-01 Trial Reports 83% PSA50 Response in Patients Without Prior Lu-PSMA

/in , , /by

New results from the phase 2 CONVERGE-01 trial,  show preliminary antitumor activity of CONV01-α, an experimental PSMA-targeted alpha therapy, in patients with metastatic androgen pathway inhibitor-resistant prostate cancer (mCRPC) who had not previously received Lu-PSMA radioligand therapy. CONV01-α, also known as ²²⁵Ac-rosopatamab tetraxetan, combines the alpha-emitting isotope actinium-225 with a monoclonal antibody targeting PSMA. Unlike […]

Read more

UPDATE: Gedatolisib Plus Darolutamide Shows Activity in mCRPC

/in , , , /by

Updated results from the phase 1/2 CELC-G-201 trial (we talked about it in this previous article) provide new evidence of antitumor activity for gedatolisib combined with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with androgen receptor pathway inhibitors (ARPIs). Gedatolisib inhibits the PI3K–AKT–mTOR signaling pathway, which can contribute to resistance to […]

Read more

Phase 1 Trial of SYNC-T Immunotherapy Reports Longer-Term Survival Data in Prostate Cancer

/in , , /by

Updated results provide longer-term survival data for SYNC-T Therapy SV-102, an experimental personalized immunotherapy evaluated in patients with metastatic prostate cancer. SYNC-T uses a two-step approach. First, a selected tumor lesion undergoes partial cryolysis, releasing patient-specific tumor antigens. An immunotherapy mixture called SV-102 is then injected directly into the treated area. It contains four components: […]

Read more

Phase 2 ExBAT Trial: AR Amplification Linked to Poorer Outcomes With Alternating Testosterone and Darolutamide

/in , , /by

New biomarker findings from the phase 2 ExBAT trial, suggest that androgen receptor (AR) amplification may be associated with poorer outcomes in patients receiving alternating bipolar androgen therapy (BAT) and darolutamide for metastatic castration-resistant prostate cancer (mCRPC). ExBAT/LACOG 0620 investigated an experimental strategy combining periods of supraphysiological testosterone exposure with subsequent androgen receptor inhibition. Patients […]

Read more